Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics Publisher Pubmed



Ebrahimi N1 ; Aslani S2 ; Babaie F3, 4 ; Hemmatzadeh M5 ; Hosseinzadeh R4 ; Joneidi Z6 ; Mehdizadeh Tourzani Z7 ; Pakravan N8 ; Mohammadi H8, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of International Medicine, Faculty of Medicine, Health Sciences University, Istanbul, Turkey
  2. 2. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran
  4. 4. Department of Medical Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
  5. 5. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
  6. 6. Faculty of Nursing, Bank Meli Iran, Tehran, Iran
  7. 7. Department of Midwifery, Alborz University of Medical Sciences, Karaj, Iran
  8. 8. Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
  9. 9. Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

Source: International Immunopharmacology Published:2020


Abstract

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) is responsible for recent ongoing public health emergency in the world. Sharing structural and behavioral similarities with its ancestors [SARS and Middle East Respiratory Syndrome (MERS)], SARS-CoV-2 has lower fatality but faster transmission. We have gone through a long path to recognize SARS and MERS, therefore our knowledge regarding SARS-CoV-2 is not raw. Various responses of the immune system account for the wide spectrum of clinical manifestations in Coronavirus disease-2019 (COVID-19). Given the innate immune response as the front line of defense, it is immediately activated after the virus entry. Consequently, adaptive immune response is activated to eradicate the virus. However, this does not occur in every case and immune response is the main culprit causing the pathological manifestations of COVID-19. Lethal forms of the disease are correlated with inefficient and/or insufficient immune responses associated with cytokine storm. Current therapeutic approach for COVID-19 is in favor of suppressing extreme inflammatory responses, while maintaining the immune system alert and responsive against the virus. This could be contributing along with administration of antiviral drugs in such patients. Furthermore, supplementation with different compounds, such as vitamin D, has been tested to modulate the immune system responses. A thorough understanding of chronological events in COVID-19 contributing to the development of a highly efficient treatment has not figured out yet. This review focuses on the virus-immune system interaction as well as currently available and potential therapeutic approaches targeting immune system in the treatment of COVID-19 patients. © 2020 Elsevier B.V.
Other Related Docs
18. Immune-Based Therapy for Covid-19, Advances in Experimental Medicine and Biology (2021)
20. Covid-19 Infection and Stroke Risk, Reviews in the Neurosciences (2021)
30. Immune Profiling of Sars-Cov-2; What We Know and What We Don’T Know, Iranian Journal of Allergy# Asthma and Immunology (2023)
34. Case Fatality Rate of Covid-19: A Systematic Review and Meta-Analysis, Journal of Preventive Medicine and Hygiene (2021)
36. Dynamic Changes of Lymphocyte Subsets in the Course of Covid-19, International Archives of Allergy and Immunology (2021)
38. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
41. Potential Antiviral Immune Response Against Covid-19: Lessons Learned From Sars-Cov, Advances in Experimental Medicine and Biology (2021)
45. Coronavirus: Pure Infectious Disease or Genetic Predisposition, Advances in Experimental Medicine and Biology (2021)
49. Anticoagulant Therapy in Covid-19: A Narrative Review, Clinical and Translational Science (2023)